Somerset, N.J. (PRWEB) November 12, 2014
The Catalent Applied Drug Delivery Institute has been selected to present at the 6th annual Partnering for Cures conference, November 16-18 in New York City. Convened by FasterCures, the Washington, D.C. based center of the Milken Institute, the conference will bring together nearly 1,000 medical research leaders, investors and decision-makers to forge the collaborations needed to speed and improve outcomes-driven R&D.
Ms. Terry Robinson and Dr. Randy Mrsny from the Catalent Institute will share the goals of the Catalent Applied Drug Delivery Institute’s Non-Invasive Macromolecule Delivery Consortium (NMDC), focused on advancing the delivery of proteins, peptides and vaccines by non-invasive or minimally invasive methods, and explain how advances will be achieved using the pioneering, collaborative efforts of both industry and academic members of the Institute. The panel session takes place at 10:45am on Monday November 17, as part of the conference’s Innovator Presentation Agenda.
The Catalent Applied Drug Delivery Institute is one of 30 innovator organizations presenting their cross-sector research collaboration to potential partners and funders at the conference. Selected through a competitive proposal process, each partnership is aimed at reducing the time and cost of getting new medical solutions from discovery to patients.
“We are honored to be invited to present at this conference and to be able to share the vision and approach we have set out to achieve in the area of non-invasive delivery,” commented Terry Robinson, Executive Director, Catalent Institute. “The goal of the Catalent Institute as a whole is to improve patient experience by forging innovative collaborations between industry leaders, technology innovators and pioneering academic research, a goal that is aligned to that of FasterCures and the Milken Institute.”
Partnering for Cures is designed to facilitate informed investments and cultivate relationships, adapting the outcomes-oriented approach of investor conferences, and building on the networking opportunities at industry partnering meetings. In addition to innovator presentations, it also features panels that spotlight solutions to long-standing challenges in medical research.
“These collaborations address some of the thorniest issues in medical research using models that can be scaled and translated across diseases,” said FasterCures’ Executive Director Margaret Anderson. “From re-imagining clinical trial infrastructure to improving and expanding data sharing, to creating the tools and resources needed to translate basic science into cures, they are accelerating the path from lab to market for novel – and needed – therapies.”
For more information and to register for the conference, go to http://www.partneringforcures.org
Established in 2012, the Catalent Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies through industry and academic collaboration, research, education, and the sharing of information. In June 2014, the Institute created the NMDC and established a number of working groups looking at alternative delivery routes to injection for biologics and other large molecule therapeutics. The working groups include oral, pulmonary/nasal, ocular and transdermal delivery and welcome new members who wish to support innovation in non-invasive drug delivery.
For more details on the Catalent Institute, visit http://www.drugdeliveryinstitute.com and follow the Catalent Institute on Twitter: @DrugDeliveryIns
About the Catalent Applied Drug Delivery Institute
Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments and foster industry collaboration on major issues pertaining to drug development, formulation and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™